Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

about

5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity.

P2860

Q37986694-DBFC06BD-818B-47DD-B7E8-D23AE425F015

P2860

Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

Item

http://www.wikidata.org/entity/Q35750211

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

@ast

Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

@en

type

Item

label

Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

@ast

Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

@en

prefLabel

Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

@ast

Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

@en

P1476

Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

@en

P2093

Robert A Kloner

http://www.w3.org/2001/XMLSchema#string

Wangde Dai

http://www.w3.org/2001/XMLSchema#string

P2860

COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Do human platelets express COX-2?

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

Prostaglandin H synthase and vascular function

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

Biomedicine. Back to an aspirin a day?

Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study

P304

51-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/107424840400900I108

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15094969

http://www.w3.org/2001/XMLSchema#string

Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

about

P2860

P2860

Relationship between cyclooxygenase-2 inhibition and thrombogenesis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698